Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Evogene ( (EVGN) ) has shared an update.
On May 21, 2025, Evogene Ltd. announced its financial results for the first quarter of 2025, highlighting a decrease in total revenues to approximately $2.4 million from $4.2 million in the same period of 2024. This decline was primarily due to the absence of significant license fee payments received in 2024. The company has implemented an expense reduction plan, reflected in reduced R&D and operating expenses for the quarter. Additionally, Evogene announced the acquisition of most of Lavie Bio’s operations by ICL for $15.25 million, expected to generate direct and indirect value for the company. This strategic move aligns with Evogene’s focus on capital efficiency and value generation from its subsidiaries, positioning the company for sustainable growth in the life sciences industry.
The most recent analyst rating on (EVGN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Underperform.
Evogene’s overall stock score is low, primarily due to weak financial performance marked by negative earnings and cash flow, and technical indicators pointing to a lack of upward momentum. Despite positive developments in partnerships and revenue growth, the fundamental financial instability overshadows these gains. Valuation challenges and operational inefficiencies further weigh down the score.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd. is a leading computational biology company focused on revolutionizing the development of life-science-based products. The company operates in the pharmaceutical and agricultural sectors, utilizing its proprietary AI platforms such as ChemPass-AI and MicroBoost AI to develop innovative solutions. Evogene’s market focus includes small molecule drug discovery and microbiome-based agricultural products, with subsidiaries like Lavie Bio, Casterra, AgPlenus, and Biomica contributing to its diverse portfolio.
Average Trading Volume: 383,163
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.94M
Learn more about EVGN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue